Compare CRGO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRGO | CHRS |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.4M | 186.0M |
| IPO Year | N/A | 2014 |
| Metric | CRGO | CHRS |
|---|---|---|
| Price | $2.32 | $1.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.02 |
| AVG Volume (30 Days) | 72.5K | ★ 861.2K |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.34 |
| Revenue | $28,642,000.00 | ★ $277,728,000.00 |
| Revenue This Year | $26.59 | N/A |
| Revenue Next Year | $23.43 | $67.31 |
| P/E Ratio | ★ N/A | $2.53 |
| Revenue Growth | 27.55 | ★ 152.07 |
| 52 Week Low | $1.72 | $0.71 |
| 52 Week High | $4.42 | $1.89 |
| Indicator | CRGO | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 25.25 | 48.49 |
| Support Level | $2.27 | $1.30 |
| Resistance Level | $2.72 | $1.43 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 8.42 | 43.75 |
Freightos Ltd operates as a vendor-neutral booking and payment platform for international freight. Its platform supports supply chain efficiency and agility by enabling real-time procurement of ocean and air shipping across more than ten thousand importers/exporters. forwarders, and dozens of airlines and ocean carriers. WebCargo by Freightos is a freight platform connecting carriers and forwarders in particular an air cargo eBooking platform. Freightos.com is a digital international freight marketplace for importers and exporters for instant pricing, booking, and shipment management. The company operates in two segments-Platform segment and Solutions segment. Geographically, the company operates in Europe, Hong Kong, United States which is majority revenue generator and others.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.